Kindred Biosciences, Inc. (KIN)

4.0500 -0.1400 (-3.34%) At close: 4:00PM EDT

Kindred Biosciences, Inc.

1555 Bayshore Highway
Suite 200
Burlingame, CA 94010
United States
650-701-7901
http://www.kindredbio.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 156

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Richard Chin	Co-Founder, CEO & Director	899k	N/A	1967
Ms. Denise M. Bevers	Co-Founder, Sec. & Director	633.13k	N/A	1967
Ms. Wendy K. Wee	Chief Financial Officer	438.15k	N/A	1953
Dr. Hangjun Zhan	Chief Scientific Officer	432.98k	N/A	1960
Ms. Katja Buhrer	Chief of Staff, VP of Corp. Devel. & Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

Corporate Governance

Kindred Biosciences, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.